<p>根据 Campbell &amp; CO Investment Adviser LLC 最近向 SEC 提交的文件，该公司在第三季度购买了 AbbVie Inc.（纽约证券交易所代码：ABBV - 免费报告）的新股份。该公司购买了 5,480 股，价值约为 1,269,000 美元。</p>
<ul>
<li>3 只 “永恒股票” 在市场不稳定时持有</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Vanguard Group Inc.在第二季度将其在 AbbVie 的持股增加了 1.9%。Vanguard Group Inc.目前拥有 177,298,707 股该公司的股票，价值 32,910,186,000 美元，此前在上个季度又购买了 3,380,842 股。Geode Capital Management LLC 在第二季度将其在 AbbVie 的股份增加了 2.4%。Geode Capital Management LLC 目前拥有 39,178,351 股该公司的股票，价值 7,240,169,000 美元，此前在上个季度又购买了 924,761 股。Charles Schwab Investment Management Inc.在第二季度将其在 AbbVie 的持股增加了 6.0%。Charles Schwab Investment Management Inc.目前拥有 26,783,329 股该公司的股票，价值 4,970,848,000 美元，此前在上个季度又购买了 1,517,222 股。挪威银行在第二季度收购了 AbbVie 的新股份，价值 4,288,200,000 美元。最后，Raymond James Financial Inc.在第二季度将其在 AbbVie 的持股增加了 41.8%。Raymond James Financial Inc.目前拥有 9,337,480 股该公司的股票，价值 1,733,222,000 美元，此前在上个季度又购买了 2,753,312 股。70.23% 的股票由机构投资者和对冲基金持有。</p>
<h2>更多 AbbVie 新闻</h2>
<p>以下是本周影响 AbbVie 的主要新闻：</p>
<ul>
<li>积极情绪：Zacks Research 上调了 AbbVie 多个短期和 2026 财年-2027 财年的每股收益（EPS）预期，表明分析师预计未来几个季度将有更强的盈利势头。Zacks：AbbVie 股票下跌——关键事实</li>
<li>积极情绪：AbbVie 正在扩展其肿瘤学管线——启动了针对晚期鳞状肿瘤的首个人体试验 ABBV-711，这支持了超越免疫学的长期收入多样化。TipRanks：ABBV 启动 ABBV-711 试验</li>
<li>积极情绪：AbbVie 继续推进新类别：完成了针对肥胖候选药物（GUB014295）的首个人体试验工作以及其他早期项目，表明未来有多个增长途径。TipRanks：肥胖管线更新</li>
<li>积极情绪：Skyrizi 再次成为全年电视广告支出最高者——持续的重度营销应支持 AbbVie 的一个增长驱动因素的持续增长和收入增长。FiercePharma：Skyrizi 成为电视广告支出最高者</li>
<li>中性情绪：AbbVie 发布了来自第三阶段 EPCORE DLBCL-1 试验的 epcoritamab（DuoBody CD3xCD20）的顶线结果，并表示将与全球监管机构讨论下一步——公司声明，并不是明确的批准路径。PR Newswire：AbbVie 顶线 EPCORE DLBCL-1</li>
<li>消极情绪：几份市场报告将 EPCORE 的结果描述为在生存终点上的临床失望（尽管有无进展生存期信号），这导致合作伙伴 Genmab 的卖压，并使 AbbVie 近期肿瘤学的上行风险受到威胁。这种混合/未达标的生存信息是今天股价疲软的主要原因。Seeking Alpha：Genmab 在 Epkinly 试验数据后下跌</li>
</ul>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>AbbVie 看涨期权激增 2599%：追踪大额押注</li>
</ul>
<p>多家券商最近对 ABBV 发表了评论。Scotiabank 在 11 月 13 日的研究报告中开始覆盖 AbbVie。他们给予了 “行业表现优于大盘” 的评级，并设定了 280.00 美元的目标价。Guggenheim 在 10 月 20 日的研究报告中将 AbbVie 的目标价从 227.00 美元上调至 242.00 美元，并给予该股票 “买入” 评级。Piper Sandler 在 11 月 5 日的研究报告中重新发布了 “增持” 评级，并设定了 289.00 美元的目标价（上调自 284.00 美元）。DZ Bank 在 11 月 4 日的研究报告中将 AbbVie 的评级从 “买入” 下调至 “持有”，并设定了 237.00 美元的目标价。最后，摩根士丹利在 12 月 12 日的研究报告中将 AbbVie 的目标价从 261.00 美元上调至 269.00 美元，并给予该公司 “增持” 评级。三家股票研究分析师对该股票给予了强烈买入评级，十三家给予了买入评级，八家给予了持有评级。根据 MarketBeat.com，该股票的共识评级为 “适度买入”，共识目标价为 247.84 美元。</p>
<p><strong>获取我们关于 ABBV 的最新报告</strong></p>
<h2>AbbVie 价格表现</h2>
<ul>
<li>该 ETF 证明医疗保健反弹是真实的</li>
</ul>
<p>AbbVie 股票在周一开盘价为 214.38 美元。该公司的市值为 3788.9 亿美元，市盈率为 162.41，市盈增长比率为 0.88，贝塔值为 0.36。AbbVie Inc.的 12 个月低点为 164.39 美元，12 个月高点为 244.81 美元。该公司的 50 日简单移动平均为 226.80 美元，200 日简单移动平均为 216.65 美元。</p>
<p>AbbVie（纽约证券交易所代码：ABBV - 获取免费报告）最近在 10 月 31 日发布了季度财报。该公司报告每股收益（EPS）为 1.86 美元，超出市场共识预期的 1.77 美元，超出 0.09 美元。AbbVie 的股本回报率为 3,216.47%，净利润率为 4.00%。该公司在本季度的收入为 157.8 亿美元，而分析师的预期为 155.8 亿美元。在去年同期，该公司每股收益为 3.00 美元。该公司本季度的收入同比增长 9.1%。AbbVie 已将其 2025 年第四季度的指导目标设定为 3.320-3.360 EPS。分析师平均预测 AbbVie Inc.在当前财年将发布 12.31 美元的每股收益。</p>
<h2>AbbVie 增加股息</h2>
<p>该公司最近宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）登记在册的股东将获得每股 1.73 美元的股息。这代表着每年 6.92 美元的股息和 3.2% 的收益率。这是对 AbbVie 之前每股 1.64 美元季度股息的积极调整。除息日为 1 月 16 日（星期五）。AbbVie 目前的股息支付比率（DPR）为 496.97%。</p>
<h2>AbbVie 公司简介</h2>
<p>（免费报告）</p>
<p>AbbVie 是一家全球性的、以研究为驱动的生物制药公司，成立于 2013 年，作为雅培实验室的分拆公司，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗状况的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将特种药物推向多个治疗领域的市场。</p>
<p>AbbVie 的产品组合和研发管线涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 AbbVie</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
<p><strong>想看看其他对 ABBV 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取 AbbVie Inc.（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 AbbVie 吗？</h2>
<p>在您考虑 AbbVie 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 AbbVie 并不在名单上。</p>
<p>虽然 AbbVie 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>Campbell & CO Investment Adviser LLC 在第三季度收购了 5,480 股艾伯维（AbbVie Inc.，NYSE:ABBV），价值约 127 万美元。其他机构投资者，包括先锋集团（Vanguard）和吉奥德资本（Geode Capital），也增加了对艾伯维的持股。分析师对艾伯维的看法不一，有些人提高了价格目标和评级，而另一些人则对最近的临床试验结果表示担忧。该股票的共识评级为 “适度买入”，价格目标为 247.84 美元，目前市值为 3788.9 亿美元</p>

<p>Campbell &amp; CO Investment Adviser LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 5,480 shares of the company's stock, valued at approximately $1,269,000.</p>
<div class="lb-trans"><p>根据 Campbell &amp; CO Investment Adviser LLC 最近向 SEC 提交的文件，该公司在第三季度购买了 AbbVie Inc.（纽约证券交易所代码：ABBV - 免费报告）的新股份。该公司购买了 5,480 股，价值约为 1,269,000 美元。</p>
</div><ul>
<li>3 “Forever Stocks” to Hold When the Market Won’t Sit Still</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只 “永恒股票” 在市场不稳定时持有</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC lifted its stake in AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company's stock valued at $7,240,169,000 after buying an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company's stock valued at $4,970,848,000 after buying an additional 1,517,222 shares during the last quarter. Norges Bank acquired a new stake in AbbVie during the 2nd quarter valued at $4,288,200,000. Finally, Raymond James Financial Inc. increased its position in AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock worth $1,733,222,000 after buying an additional 2,753,312 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Vanguard Group Inc.在第二季度将其在 AbbVie 的持股增加了 1.9%。Vanguard Group Inc.目前拥有 177,298,707 股该公司的股票，价值 32,910,186,000 美元，此前在上个季度又购买了 3,380,842 股。Geode Capital Management LLC 在第二季度将其在 AbbVie 的股份增加了 2.4%。Geode Capital Management LLC 目前拥有 39,178,351 股该公司的股票，价值 7,240,169,000 美元，此前在上个季度又购买了 924,761 股。Charles Schwab Investment Management Inc.在第二季度将其在 AbbVie 的持股增加了 6.0%。Charles Schwab Investment Management Inc.目前拥有 26,783,329 股该公司的股票，价值 4,970,848,000 美元，此前在上个季度又购买了 1,517,222 股。挪威银行在第二季度收购了 AbbVie 的新股份，价值 4,288,200,000 美元。最后，Raymond James Financial Inc.在第二季度将其在 AbbVie 的持股增加了 41.8%。Raymond James Financial Inc.目前拥有 9,337,480 股该公司的股票，价值 1,733,222,000 美元，此前在上个季度又购买了 2,753,312 股。70.23% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>More AbbVie News</h2>
<div class="lb-trans"><h2>更多 AbbVie 新闻</h2>
</div><p>Here are the key news stories impacting AbbVie this week:</p>
<div class="lb-trans"><p>以下是本周影响 AbbVie 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts</li>
<li>Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial</li>
<li>Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update</li>
<li>Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender</li>
<li>Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1</li>
<li>Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Zacks Research 上调了 AbbVie 多个短期和 2026 财年-2027 财年的每股收益（EPS）预期，表明分析师预计未来几个季度将有更强的盈利势头。Zacks：AbbVie 股票下跌——关键事实</li>
<li>积极情绪：AbbVie 正在扩展其肿瘤学管线——启动了针对晚期鳞状肿瘤的首个人体试验 ABBV-711，这支持了超越免疫学的长期收入多样化。TipRanks：ABBV 启动 ABBV-711 试验</li>
<li>积极情绪：AbbVie 继续推进新类别：完成了针对肥胖候选药物（GUB014295）的首个人体试验工作以及其他早期项目，表明未来有多个增长途径。TipRanks：肥胖管线更新</li>
<li>积极情绪：Skyrizi 再次成为全年电视广告支出最高者——持续的重度营销应支持 AbbVie 的一个增长驱动因素的持续增长和收入增长。FiercePharma：Skyrizi 成为电视广告支出最高者</li>
<li>中性情绪：AbbVie 发布了来自第三阶段 EPCORE DLBCL-1 试验的 epcoritamab（DuoBody CD3xCD20）的顶线结果，并表示将与全球监管机构讨论下一步——公司声明，并不是明确的批准路径。PR Newswire：AbbVie 顶线 EPCORE DLBCL-1</li>
<li>消极情绪：几份市场报告将 EPCORE 的结果描述为在生存终点上的临床失望（尽管有无进展生存期信号），这导致合作伙伴 Genmab 的卖压，并使 AbbVie 近期肿瘤学的上行风险受到威胁。这种混合/未达标的生存信息是今天股价疲软的主要原因。Seeking Alpha：Genmab 在 Epkinly 试验数据后下跌</li>
</ul>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>AbbVie Call Options Spike 2,599%: Tracking the Big Bet</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 看涨期权激增 2599%：追踪大额押注</li>
</ul>
</div><p>A number of brokerages have recently commented on ABBV. Scotiabank assumed coverage on AbbVie in a research report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $280.00 price objective for the company. Guggenheim boosted their price objective on AbbVie from $227.00 to $242.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, October 20th. Piper Sandler reissued an &#34;overweight&#34; rating and issued a $289.00 price objective (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. DZ Bank lowered shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $237.00 price target for the company. in a research note on Tuesday, November 4th. Finally, Morgan Stanley upped their price objective on AbbVie from $261.00 to $269.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, December 12th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $247.84.</p>
<div class="lb-trans"><p>多家券商最近对 ABBV 发表了评论。Scotiabank 在 11 月 13 日的研究报告中开始覆盖 AbbVie。他们给予了 “行业表现优于大盘” 的评级，并设定了 280.00 美元的目标价。Guggenheim 在 10 月 20 日的研究报告中将 AbbVie 的目标价从 227.00 美元上调至 242.00 美元，并给予该股票 “买入” 评级。Piper Sandler 在 11 月 5 日的研究报告中重新发布了 “增持” 评级，并设定了 289.00 美元的目标价（上调自 284.00 美元）。DZ Bank 在 11 月 4 日的研究报告中将 AbbVie 的评级从 “买入” 下调至 “持有”，并设定了 237.00 美元的目标价。最后，摩根士丹利在 12 月 12 日的研究报告中将 AbbVie 的目标价从 261.00 美元上调至 269.00 美元，并给予该公司 “增持” 评级。三家股票研究分析师对该股票给予了强烈买入评级，十三家给予了买入评级，八家给予了持有评级。根据 MarketBeat.com，该股票的共识评级为 “适度买入”，共识目标价为 247.84 美元。</p>
</div><p><strong>Get Our Latest Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 ABBV 的最新报告</strong></p>
</div><h2>AbbVie Price Performance</h2>
<div class="lb-trans"><h2>AbbVie 价格表现</h2>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>该 ETF 证明医疗保健反弹是真实的</li>
</ul>
</div><p>AbbVie stock opened at $214.38 on Monday. The stock has a market capitalization of $378.89 billion, a PE ratio of 162.41, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a 50 day simple moving average of $226.80 and a 200-day simple moving average of $216.65.</p>
<div class="lb-trans"><p>AbbVie 股票在周一开盘价为 214.38 美元。该公司的市值为 3788.9 亿美元，市盈率为 162.41，市盈增长比率为 0.88，贝塔值为 0.36。AbbVie Inc.的 12 个月低点为 164.39 美元，12 个月高点为 244.81 美元。该公司的 50 日简单移动平均为 226.80 美元，200 日简单移动平均为 216.65 美元。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to analysts' expectations of $15.58 billion. During the same period last year, the firm earned $3.00 EPS. The firm's revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>AbbVie（纽约证券交易所代码：ABBV - 获取免费报告）最近在 10 月 31 日发布了季度财报。该公司报告每股收益（EPS）为 1.86 美元，超出市场共识预期的 1.77 美元，超出 0.09 美元。AbbVie 的股本回报率为 3,216.47%，净利润率为 4.00%。该公司在本季度的收入为 157.8 亿美元，而分析师的预期为 155.8 亿美元。在去年同期，该公司每股收益为 3.00 美元。该公司本季度的收入同比增长 9.1%。AbbVie 已将其 2025 年第四季度的指导目标设定为 3.320-3.360 EPS。分析师平均预测 AbbVie Inc.在当前财年将发布 12.31 美元的每股收益。</p>
</div><h2>AbbVie Increases Dividend</h2>
<div class="lb-trans"><h2>AbbVie 增加股息</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.2%. This is a positive change from AbbVie's previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie's dividend payout ratio (DPR) is presently 496.97%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）登记在册的股东将获得每股 1.73 美元的股息。这代表着每年 6.92 美元的股息和 3.2% 的收益率。这是对 AbbVie 之前每股 1.64 美元季度股息的积极调整。除息日为 1 月 16 日（星期五）。AbbVie 目前的股息支付比率（DPR）为 496.97%。</p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>AbbVie 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.</p>
<div class="lb-trans"><p>AbbVie 是一家全球性的、以研究为驱动的生物制药公司，成立于 2013 年，作为雅培实验室的分拆公司，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗状况的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将特种药物推向多个治疗领域的市场。</p>
</div><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p>
<div class="lb-trans"><p>AbbVie 的产品组合和研发管线涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 AbbVie</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ABBV 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取 AbbVie Inc.（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 AbbVie 吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 AbbVie 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 AbbVie 并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 AbbVie 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Campbell & CO Investment Adviser LLC 购买了 5,480 股艾伯维公司（AbbVie Inc.）的股票 $ABBV